Rigel Pharmaceuticals, Inc.

Equities

RIGL

US7665596034

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
1.48 USD -0.67% Intraday chart for Rigel Pharmaceuticals, Inc. +2.07% +2.07%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer as Chief Medical Officer CI
Citigroup Adjusts Rigel Pharmaceuticals' Price Target to $4 From $3, Maintains Buy Rating MT
Transcript : Rigel Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 05, 2024
Rigel Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Posts Q4 Revenue $35.8M, vs. Street Est of $33.4M MT
Rigel Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
B. Riley Lifts Rigel Pharmaceuticals' PT to $1.75 From $1.25 After Announced Purchase of US Rights to Gavreto From Blueprint Medicines; Keeps Neutral Rating MT
Rigel Pharmaceuticals Seeks Acquisitions CI
Transcript : Rigel Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 12:00 PM
Rigel Pharmaceuticals Enters Collaboration to Study Possible Treatment for Brain Tumors; Shares Rise MT
Rigel Pharmaceuticals, Inc. Announces Collaboration with Connect to Conduct a Phase 2 Trial of Olutasidenib in Glioma CI
Rigel Pharmaceuticals, Inc. and The University of Texas MD Anderson Cancer Center Announce Strategic Alliance to Advance REZLIDHIA®? (Olutasidenib) in AML and Other Cancers CI
Rigel Pharmaceuticals, MD Anderson Partner for Research on New Rezlidhia Indications MT
B. Riley Trims Rigel Pharmaceuticals' PT to $1.25 From $1.75, Lowers Peak Sales Estimate for Rezlidhia; Maintains Neutral Rating MT
Transcript : Rigel Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 07, 2023
Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Posts Q3 Revenue $28.1M, vs. Street Est of $27.2M MT
Rigel Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Rigel Pharmaceuticals, Inc. Announces Poster Presentations At the 65Th American Society of Hematology Annual Meeting and Exposition CI
Rigel Pharmaceuticals, Inc. Announces Presentation of Data from the Focus Phase 3 Clinical Trial of Fostamatinib in Hospitalized COVID-19 Patients and Provides Update on ACTIV-4 Host Tissue Trial CI
Athersys Names Jane Wasman as Board Chair MT
Transcript : Rigel Pharmaceuticals, Inc. Presents at Cantor Fitzgerald Annual Global Healthcare Conference 2023, Sep-27-2023 03:35 PM
Transcript : Rigel Pharmaceuticals, Inc., Q2 2023 Earnings Call, Aug 01, 2023
Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Reports Q2 Revenue $26.9M, vs. Street Est of $25.7M MT
Rigel Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Rigel Pharmaceuticals, Inc.(NasdaqGS:RIGL) added to Russell Small Cap Comp Value Index CI
Chart Rigel Pharmaceuticals, Inc.
More charts
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
1.48 USD
Average target price
4.458 USD
Spread / Average Target
+201.24%
Consensus
  1. Stock
  2. Equities
  3. Stock Rigel Pharmaceuticals, Inc. - Nasdaq
  4. News Rigel Pharmaceuticals, Inc.
  5. Rigel Pharmaceuticals Launches Rezlidhia in US for Relapsed/Refractory Acute Myeloid Leukemia